Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (May 2005)
11 slides from Medical Developments International's investor presentation, May 25, 2005
Slide 1: Medical Developments International Limited (MDI) Presentation
Medical Developments International Limited (“MDI”) Presentation Sydney – 25 May 2005
Slide 2: Introduction – MDI Profile
Introduction – MDI Profile Product Segments Medical Developments International • Pharmaceutical - Single product (PenthroxTM – inhaled analgesic) - Only manufacturer in the world - TGA & Medsafe (NZ) - Plant is GMP certified - 53% of sales - Currently used in ambulance, military, hospitals and resea
Slide 3: Growth Strategy – Penthrox
Growth Strategy – Penthrox Organic growth is expected in established markets during FY06 Methoxyflurane Growth Strategy Medical Developments International New Applications/Uses Rescue Services New Zealand Military Dubai Police Current Ambulance Research Institutions Research Institutions Australia T
Slide 4: Methoxyflurane Growth Strategy (Domestic)
Growth Strategy – Penthrox (Domestic) There are exciting growth prospects in new applications in Australia in FY06, particularly in dentistry Methoxyflurane Growth Strategy Medical Developments International • Market potential – multiples of ambulance • Trial complete in June ’05 Dentists (Australia
Slide 5: Penthrox addresses the major issues in dentistry: pain and anxiety management
Growth Strategy – Penthrox (Domestic) PenthroxTM addresses the major issues in dentistry: pain and anxiety management Medical Developments International Examples of Use Trial Results* • Administration of local anaesthetic Question Positive Response • Initial examination of patients in pain Nervousne
Slide 6: Methoxyflurane Growth Strategy (International)
Growth Strategy – Penthrox (International) International growth in FY06 could be exciting in new markets where registration is obtained Methoxyflurane Growth Strategy Medical Developments International • Market > 200 million people Dentists • Distributors appointed • Marketing & sales material disse
Slide 7: Operational Capacity
Operational Capacity There is sufficient manufacturing capacity to meet prospective demand in FY2006 Medical Developments International Manufacturing Infrastructure Capacity sufficient to meet prospective demand in 2006 Capex of $120k to install capacity for further growth “Greenfields” plan
Slide 8: Medical Devices distribution arrangements
Growth Strategy – Medical Devices In FY06, growth should be moderate. The focus will be on optimising the value of existing distribution arrangements together with making select new appointments Current Distribution Arrangements (to be leveraged) Medical Developments International United Kingdom Ira
Slide 9: MDI Financial Profile
MDI Financial Profile MDI is profitable despite making significant investments in growth Key Financials Medical Developments International (as at 31 December 2004) $000 Revenue 2850 EBITDA 555 NPAT 117 ---------------------------------------------------- Key Investments in Growth (6 months to 31 Dec
Slide 10: FY05 Prognosis
FY05 Prognosis Sales will exceed FY04 sales (annualised) but are unlikely to meet forecast due to lower than forecast sales in Medical Devices Product Comment Medical Developments International PenthroxTM Ambulance growth in line with forecast Expect orders from Pakistan Military, UAE Military & Oz
Slide 11: Closing Comments
Closing Comments Medical Developments International • Base of existing revenue, cashflow and profits • PenthroxTM will be the growth engine in FY2006 with significant sales likely in Dentistry, the Middle East and Asia • PenthroxTM sales in hospitals and GP’s will grow more slowly • Moderate growth
Medical Developments International — Investor Presentation (May 2005) on 6ix